IO Biotech, Inc. (NASDAQ:IOBT) is among the 11 Low Price High Volume Stocks to Buy According to Analysts. On August 15, H.C. Wainwright reiterated a Purchase ranking on IO Biotech, Inc. (NASDAQ:IOBT), protecting its worth goal at $14.
Emily Bodnar from H.C. Wainwright maintained the ranking on IOBT based mostly on the corporate’s current improvement and future potential. The corporate’s pivotal part 3 trial for the Cylembio remedy confirmed a clinically significant enchancment in progression-free survival (PFS) for sufferers affected by superior melanoma. The analyst stays constructive on the corporate’s improvement although the trial narrowly missed its major endpoint.
A biopharmaceutical analysis laboratory full of scientists, illuminated by the glow of their tools.
The corporate plans to submit a biologics license software to the U.S. FDA for Cylembio by the tip of 2025. Furthermore, IO Biotech’s pipeline consists of promising part 2 trials for different most cancers varieties, with information anticipated within the close to future. Bodnar sees these elements as contributing to the constructive outlook. The corporate’s modern therapies have the potential to deal with unmet medical wants in oncology.
IO Biotech, Inc. (NASDAQ:IOBT) is a clinical-stage biopharmaceutical agency that develops immune-modulating therapeutic most cancers therapies or vaccines based mostly on the T-win know-how platform.
Whereas we acknowledge the potential of IOBT as an funding, we consider sure AI shares supply better upside potential and carry much less draw back threat. In case you’re searching for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This text is initially printed at Insider Monkey.
